Vaxart entered into a Cooperation Agreement with a Stockholder Group to resolve a proxy contest and enhance governance. The group withdrew its director nominations and books-and-records demand, and will work with Vaxart within 60–90 days after the 2026 annual meeting to seat a mutually agreed independent director who will chair a new Stockholder Engagement Committee. Vaxart will also adopt a director resignation policy, director stock ownership guidelines, and form a Clinical and Regulatory Affairs Committee, while meeting quarterly with the group under a standstill and voting commitment. The company will reimburse up to $650,000 of the group’s documented expenses; the agreement runs until a date tied to the 2027 meeting, extendable to the 2028 cycle if the new director is renominated.
Agreement details:
- Agreement type: Cooperation Agreement (activist settlement and governance framework)
- Counterparty: Stockholder Group (Daniel P. Houle, Mark Silverberg, Matthew M. Wallace, Patrice Raffy, Q3 Nominees, Marc Eustace Pereira)
- Signed / Effective: Jul 01 2026 / same
- Duration / Termination: Until a date tied to the 2027 meeting; extendable to 2028
- Reason: Resolve proxy contest and enhance governance and engagement
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.